SEC Form 10-Q filed by Petros Pharmaceuticals Inc.
$PTPI
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Delivers Overview of New Strategy for Leveraging AMMO's Existing Assets and Evolving the Company into a Diversified, Growing and Profitable Ecommerce Powerhouse Highlights Long-Term Opportunity to Achieve $1 Billion in Annual Sales with Strong Cash Flows and Sustainable Margins, Resulting in Superior Value Creation for Shareholders Introduces Diverse Slate with Expertise in Corporate Governance, Ecommerce, Finance, M&A and Strategic Growth Across Relevant B2B and B2C Categories Steven Urvan (together with the other participants in his solicitation, the "Urvan Group" or "we"), who owns approximately 17.1% of the outstanding common shares of AMMO, Inc. (NASDAQ:POWW) ("AMMO" or the "Co
NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces financial results for the fiscal year ended December 31, 2021. Recent Corporate Highlights: Entered collaboration with Dr. Drew Pinsky to bring awareness to men's health with a focus on driving awareness around erectile and other sexual dysfunctionsPartnered with leading global contract manufacturer to bring production of erectile dysfunction drug STENDRA® to the United StatesLaunched two self-selection studies for erectile dysfunction drug STENDRA®Announced positive over-the-counter (OTC) label compr
Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussionsNEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial study to determine consumer comprehension of the messaging in its App Technology ("App Comp"), which has unique differences from the current Drug Facts Label ("DFL"). Of the 31 objectives, 29 scored >90% comprehension Point Estimate ("PE"), 30 scored >86.7% comprehension PE, and all scored >80% compreh
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development programs, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.Presentation Date: September 9, 2024Time: Available on-demand starting at 7:00 AM ETInvestors who wish to listen to the Company's presentation can do so by registering for the conference here: https://hcwevents.com/annualco
Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts to potentially create a first-ever Rx-to-OTC switch in the ED categoryNEW YORK, NY / ACCESSWIRE / July 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of a subsequent analysis of its pivotal study aimed at facilitating FDA-approved OTC access of the Company's STENDRA® (avanafil) for consumers. This analysis suggested su
4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
4 - Petros Pharmaceuticals, Inc. (0001815903) (Issuer)
SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
SC 13G - Petros Pharmaceuticals, Inc. (0001815903) (Subject)
8-K - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
DEFA14A - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
10-Q - Petros Pharmaceuticals, Inc. (0001815903) (Filer)
Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor
Petros Pharmaceuticals Inc (NASDAQ:PTPI) is a pharmaceutical company focusing on men’s health therapeutics. In an interview with Benzinga, Fady Boctor, the President and Chief Commercial Officer of Petros Pharmaceuticals, said the company aims to expand access of key prescription pharmaceuticals as over-the-counter (OTC) treatment options. Boctor added that Petros is a pure play in the Rx-to-OTC self-care market, focused on bringing its current lead erectile dysfunction (ED) therapeutic OTC while developing a pathway that would take future therapeutics OTC as well. “Rx-to-OTC is emerging as a substantial self-care industry among pharmaceutical companies. According to FMI’s Rx-to-OTC
Shares of Signet Jewelers Limited (NYSE:SIG) fell sharply during Thursday's session following mixed first-quarter earnings including an 8.9% drop in same store sales. The company reported a first-quarter FY25 sales decline of 9.5% year-on-year to $1.510 billion, missing the analyst consensus estimate of $1.514 billion. Adjusted EPS of $1.11 beat the consensus estimates of 85 cents. Signet expects second-quarter sales of $1.46 billion – $1.52 billion, versus the consensus of $1.508 billion. Signet Jewelers shares dipped 12.5% to $94.81 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares climb
Gainers Longeveron (NASDAQ:LGVN) stock increased by 74.6% to $3.16 during Thursday's regular session. The company's market cap stands at $20.0 million. BioRestorative Therapies (NASDAQ:BRTX) stock rose 27.4% to $1.72. The market value of their outstanding shares is at $11.6 million. Aethlon Medical (NASDAQ:AEMD) shares rose 26.84% to $0.66. The market value of their outstanding shares is at $3.3 million. Sharps Technology (NASDAQ:STSS) stock moved upwards by 23.58% to $0.37. The company's market cap stands at $6.5 million. Biomea Fusion (NASDAQ:BMEA) stock moved upwards by 20.95% to $5.6. The market value of their outstanding shares is at $201.2 million. iSpecimen (NASDAQ:ISPC) shares